Dr. Avtar Roopra couldn’t believe what he was seeing: a medication that *stopped seizures* in mice—even AFTER they stopped taking it. No seizures. No meds. And even better? It restored cognitive function. Skeptical? So was Roopra and other scientists—until they repeated the results twice with the same outcome.

Even more shocking? This drug is already FDA-approved for other chronic conditions. So why isn’t this a breakthrough epilepsy treatment? Because NIH funding cuts have brought this promising research to a halt—and put its future in jeopardy.

Anne Morgan Giroux, founder of Lily’s Fund, which provided the seed funding for this research, joins us to explain why this matters and what you can do to help.

Donate to Lily's Fund: https://lilysfund.org/give/

Ask your reps to restore NIH funding: https://5calls.org/issue/nih-nsf-funding-cuts/

Shout out to Community Partners Epilepsy Foundation of America & the Danny Did Foundation and sponsors Neurelis & SK life science for making convos like this possible!